- Home
- ESEA vs DSGN Comparison
ESEA vs DSGN Comparison
Compare ESEA & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESEA
- DSGN
- Stock Information
- Founded
- ESEA 2005
- DSGN 2017
- Country
- ESEA Greece
- DSGN United States
- Employees
- ESEA N/A
- DSGN N/A
- Industry
- ESEA Marine Transportation
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- ESEA Consumer Discretionary
- DSGN Health Care
- Exchange
- ESEA Nasdaq
- DSGN Nasdaq
- Market Cap
- ESEA 208.2M
- DSGN 208.9M
- IPO Year
- ESEA 2006
- DSGN 2021
- Fundamental
- Price
- ESEA $48.62
- DSGN $4.00
- Analyst Decision
- ESEA Strong Buy
- DSGN Hold
- Analyst Count
- ESEA 1
- DSGN 1
- Target Price
- ESEA $62.00
- DSGN $4.00
- AVG Volume (30 Days)
- ESEA 50.8K
- DSGN 101.9K
- Earning Date
- ESEA 08-05-2025
- DSGN 08-04-2025
- Dividend Yield
- ESEA 5.33%
- DSGN N/A
- EPS Growth
- ESEA 21.86
- DSGN N/A
- EPS
- ESEA 18.62
- DSGN N/A
- Revenue
- ESEA $222,525,034.00
- DSGN N/A
- Revenue This Year
- ESEA $5.14
- DSGN N/A
- Revenue Next Year
- ESEA $3.76
- DSGN N/A
- P/E Ratio
- ESEA $2.54
- DSGN N/A
- Revenue Growth
- ESEA 14.62
- DSGN N/A
- 52 Week Low
- ESEA $24.58
- DSGN $2.60
- 52 Week High
- ESEA $50.82
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- ESEA 61.35
- DSGN 55.03
- Support Level
- ESEA $46.59
- DSGN $3.52
- Resistance Level
- ESEA $50.50
- DSGN $4.21
- Average True Range (ATR)
- ESEA 1.84
- DSGN 0.28
- MACD
- ESEA -0.13
- DSGN 0.03
- Stochastic Oscillator
- ESEA 53.62
- DSGN 77.27
About ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.